

Gilead licensed Assembly Bio's long-acting HSV drugs after Phase 1b data showed antiviral activity and weekly oral dosing potential.
You can purchase shares of Assembly Biosciences (NASDAQ:ASMB) through any online brokerage.
Other companies in Assembly Biosciences’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Assembly Biosciences has a consensus price target of $44.14.
The stock price for Assembly Biosciences (NASDAQ: ASMB) is $20.02 last updated November 4, 2026 at 2:04 PM EST.
There are no upcoming dividends for Assembly Biosciences.
Assembly Biosciences does not have any upcoming earnings scheduled.
There is no upcoming split for Assembly Biosciences.
Assembly Biosciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent...